PIVKA-II (Decarboxy Prothrombine) Test

The protein induced by vitamin K absence or antagonists-II (PIVKA-II) or Decarboxy-Prothrombine (DCP) test is used as a tumor marker to aid in the diagnosis of hepatocellular carcinoma (HCC). HCC is a primary malignancy of the liver and occurs predominantly in patients with underlying chronic liver disease and cirrhosis. Liver cancer grows silently with mild or no symptoms until advanced. In the absence of an effective treatment for advanced stage of hepatic cancer, hope lies in early detection and screening for high-risk population.

No special preparation is needed for the PIVKA-II test. But, it is recommended to do the following: Inform your doctor if you are on any medications or have any underlying medical conditions or allergies before undergoing the test. Your doctor depending on your condition will give specific instructions.

The PIVKA-II test is used for detecting vitamin K-deficient status among haemorrhagic disorders. The test result reveals the following: The normal test result for Vitamin K is 0.2 - 3.2 ng/ml for unisex gender and for all age groups. PIVKA II is < 1 microgram/ml for unisex gender and for all age groups.

The PIVKA-II test involves the following procedures: Patients undergo complete clinical examination and abdominal ultrasonography. Blood samples are collected for complete blood picture, liver and kidney function tests, Fasting blood sugar, serum potassium, and sodium levels. Hepatitis markers HBs Ag, HBs Ab, HBc Ag, and HCV Ab are detected. Diagnosis of HCC is confirmed by triphasic CT scan or liver biopsy. Serum is collected and stored at −70 °C until assayed. Level of serum AFP is detected.